| |
Significant patient populations, top clinical institutions, and ease of regulatory compliance combined to support oncology trial success in APAC. Download our white paper to explore the growth of oncology trials in APAC countries and strategies to support global study success in this dynamic and complex region. Premier Research. Built for Biotech℠
|
|
Today's Big NewsOct 17, 2022 |
|
Sino Biological offers rapid mouse monoclonal antibody development service on the Beacon®️ platform and obtains positive clones within 35 days, which accelerates the process of antibody (drug) discovery. Learn more.
|
|
| By James Waldron The long and winding road Biogen’s tofersen has taken to FDA approval just got longer, with the agency delaying its decision on the amyotrophic lateral sclerosis drug until April. |
|
|
|
By Max Bayer MacroGenics' decision to pivot its focus to its asset MGD024 appears to have paid off, with Gilead pledging up to $1.7 billion in biobucks for the phase 1 bispecific antibody. |
Sponsored By Cullinan Oncology Cullinan Oncology’s strategic approach to research and development, focusing on modality-agnostic target oncology, positions the company to thrive. |
Sponsored By PathAI TME research is recognized as one of the most promising areas in oncology drug development. AI-powered digital pathology reveals new insights previously hidden by laborious manual pathology methods. |
By Nick Paul Taylor Sage Therapeutics and Biogen have shared a closer look at phase 3 data on zuranolone in postpartum depression, presenting secondary endpoint results from SKYLARK while racing to wrap up a filing for FDA approval. |
By Gabrielle Masson As NGM Biopharmaceuticals’ phase 2 trial misses the mark, dreams for its macular degeneration treatment may be disappearing from sight. |
By Nick Paul Taylor Milestone Pharmaceuticals’ rescue mission has delivered a pivotal primary endpoint hit. Thirty months after failing its first phase 3, the nasal spray treatment for abnormal heart rhythm has beaten placebo in a second study, putting Milestone on track to file for FDA approval around the middle of next year. |
By James Waldron After a tough year marred by staff layoffs and discarded development programs, Orion Group will enter 2023 with a restructured business to reflect its amended priorities. |
By Max Bayer Matchpoint Therapeutics is unveiling with $70 million in fresh series A funds backed in part by Sanofi's venture arm. The company hopes to build a foundation with covalent chemistry, prioritizing targets in immunology. |
By Eric Sagonowsky,Angus Liu,Fraiser Kansteiner,Zoey Becker,Kevin Dunleavy What a difference five years—and a global pandemic—can make in reshaping an industry. Our latest profile of the top vaccine players includes twice the number of companies as last time along with a handful of new names. |
By Kevin Dunleavy Moderna and COVAX have canceled their existing COVID-19 vaccine supply agreement, replacing it with a deal for the company’s variant-busting shot. The new version of Moderna’s Spikevax jab will be supplied to COVAX in 2023 at the lowest figure in the company’s tiered pricing structure. The World Health Organization’s COVAX effort was established to provide low-income countries with vaccines at no or low cost. |
By Andrea Park Monday marked the first day that some hearing aids may be sold over the counter, without requiring any prescriptions, hearing tests or fitting appointments, thanks to a recently finalized—and long-awaited—ruling from the FDA. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we talk about our latest analysis on the world’s most productive biopharmas. We also discuss Biogen's tumultuous year and who it is considering for a new CEO. |
|
|---|
|
|
|
Wednesday, October 26, 2022 | 1pm ET / 10am PT In this webinar, we’ll explore how incorporating telehealth genetic screening into clinical trials can accelerate patient identification, recruitment and engagement. Register now.
|
|
| WhitepaperElectronic health records (EHR) and patient registries are both important sources of real-world evidence – but which is right for your needs? Sponsored by: Veradigm Health |
| Research Learn more about adaptive ascending dose escalation designs and considerations for determining the optimal approach to meet your drug development objectives Sponsored by: Allucent |
| eBookLooking to implement a remote patient monitoring (RPM) program at your organization? Download the eBook from Health Catalyst to learn the essential components of successful RPM programs. Sponsored by: Health Catalyst |
| eBookIn this free guide, explore how Cloud Computing is enabling emerging biopharma organizations to decrease time-to-discovery in pursuit of breakthrough treatment modalities. Sponsored by: RCH Solutions |
| eBookWith real-world data playing a significant role in health care decisions, life sciences leaders need to maximize their data investments. The best place to start is right here, with our e-book on the four steps to a more coordinated, connected real-world data strategy. Sponsored by: Optum |
| Whitepaper Learn the benefits of unlocking data insights across the healthcare and life sciences ecosystem. Sponsored by: NTT DATA |
| WhitepaperSaaS LIMS from LabVantage Solutions Is Pre-Validated for Regulated Industries, Delivering Maximum Flexibility, Uptime, and Security. Sponsored by: LabVantage Solutions Inc. |
| WhitepaperRead about key factors and trends in RWE and how our data luminaries are the right partner to lead the way forward. Sponsored by: Lumanity |
| WhitepaperThis paper is the first in a 4-part series focused on developing commercial models for gene therapies Sponsored by: Blue Matter, strategic consultants in the life sciences |
| VideoLearn how a centralized platform for pathology images, metadata, and analysis results can connect previously siloed research initiatives and advance our collective understanding of tissue. Sponsored by: Proscia |
| VideoCan an optimized research process--including AI-powered workflow and process automation tools--help get breakthrough drugs to market faster? Sponsored by: Proscia |
| WhitepaperWhat is the most suitable dosage form technology for the Oral Delivery of Lipid-Based Formulations? Sponsored by: Catalent |
| ResearchLearn more about how the versatility of Softgel Technology helped a customer with a volatile compound. Sponsored by: Catalent |
| WhitepaperHow can Lipid-Based Drug Delivery System help bring poorly soluble drugs to market? Sponsored by: Catalent |
| Whitepaper Learn how formulation development for a PFS affects manufacturing to drive the industry toward optimizing delivery of injectable products and, ultimately, improving patient care. Sponsored by: Catalent Biologics |
| WebinarYpsomed and Catalent Biologics experts discuss strategies for integrated PFS manufacturing and auto-injector assembly to accelerate timelines and more in this webinar. Sponsored by: Catalent Biologics |
| Custom Resource Center Read through this library of resources to find out how you can strengthen innovation and efficiency, improve safety and quality, and prioritize resources to support your long-term goals. Sponsored by: JLL |
| Whitepaper Clarus Therapeutics (Clarus) is a men’s specialty pharmaceutical company that partnered with Catalent to develop a unique and convenient drug delivery form for their hormone replacement therapy. Sponsored by: Catalent |
| Whitepaper Learn more about how the transition from early to late phase of a small molecule program plays a pivotal role in a program’s ultimate success. Sponsored by: Catalent |
| Whitepaper Explore how Thermo Scientific’s Process Liquid Preparation Services can help you plan for scalable buffer preparation. Sponsored by: Thermo Fisher Scientific |
| eBook Orally Inhaled & Nasal Drug Delivery: A Pipeline of Opportunities Sponsored by: Catalent |
| Whitepaper Did you know Catalent has newly expanded in-house capabilities spanning clinical and commercial scale manufacturing for DPIs, unit-dose, bi-dose and preserved multi-dose nasal sprays? Sponsored by: Catalent |
| Whitepaper What are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored by: Catalent |
| |
|
